Nothing Special   »   [go: up one dir, main page]

DOP2015000058A - Derivados tricíclicos de quinolinas y de quinoxalinas - Google Patents

Derivados tricíclicos de quinolinas y de quinoxalinas

Info

Publication number
DOP2015000058A
DOP2015000058A DO2015000058A DO2015000058A DOP2015000058A DO P2015000058 A DOP2015000058 A DO P2015000058A DO 2015000058 A DO2015000058 A DO 2015000058A DO 2015000058 A DO2015000058 A DO 2015000058A DO P2015000058 A DOP2015000058 A DO P2015000058A
Authority
DO
Dominican Republic
Prior art keywords
quinoxalinas
quinolinas
tricyclic derivatives
ht2c receptor
respond
Prior art date
Application number
DO2015000058A
Other languages
English (en)
Inventor
Andreas Haupt
Karla Drescher
Helmut Mack
Hannes Koolman
Wilfried Braje
Ana Lucia Relo
Margaretha Henrica Maria Bakker
Viktor Lakisc
Carolin Hoft
Ruxu Xu
Xiaona Zhao
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50275085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201310410951.1A external-priority patent/CN104418862A/zh
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of DOP2015000058A publication Critical patent/DOP2015000058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivadostricíclicos de quinolinas y de quinoxalinas. Composiciones far-macéuticas que los comprenden. Su uso como moduladores del receptor 5-HT2c, especialmente como agonistas o agonistas parciales. Su uso en la elabo-ración de medicamentos útiles para prevenir o tratar aquellas afecciones y aquellos trastornos que pueden responder a la modulación del receptor 5-HT2c. Método para prevenir o tratar aquellas afecciones y aquellos trastornos que pueden responder a la modulación del receptor 5-HT2c.
DO2015000058A 2012-09-14 2015-03-13 Derivados tricíclicos de quinolinas y de quinoxalinas DOP2015000058A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261701514P 2012-09-14 2012-09-14
US201261701531P 2012-09-14 2012-09-14
US201361793033P 2013-03-15 2013-03-15
CN201310410951.1A CN104418862A (zh) 2013-09-11 2013-09-11 三环喹啉和喹喔啉衍生物

Publications (1)

Publication Number Publication Date
DOP2015000058A true DOP2015000058A (es) 2015-04-15

Family

ID=50275085

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000058A DOP2015000058A (es) 2012-09-14 2015-03-13 Derivados tricíclicos de quinolinas y de quinoxalinas

Country Status (26)

Country Link
US (3) US10118926B2 (es)
EP (1) EP2895485A1 (es)
JP (1) JP6290217B2 (es)
KR (1) KR20150056608A (es)
CN (1) CN104995191A (es)
AR (1) AR092568A1 (es)
AU (2) AU2013314279B2 (es)
BR (1) BR112015005743A2 (es)
CA (1) CA2884548A1 (es)
CL (1) CL2015000628A1 (es)
CR (1) CR20150186A (es)
DO (1) DOP2015000058A (es)
EC (1) ECSP15012766A (es)
HK (1) HK1212684A1 (es)
IL (1) IL237726A0 (es)
IN (1) IN2015DN02070A (es)
MX (1) MX2015003364A (es)
NZ (1) NZ631187A (es)
PE (1) PE20150777A1 (es)
PH (1) PH12015500551A1 (es)
RU (1) RU2015113558A (es)
SG (1) SG11201501894VA (es)
TW (1) TW201414735A (es)
UA (1) UA116216C2 (es)
UY (1) UY35029A (es)
WO (1) WO2014041131A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
AR094664A1 (es) 2013-01-15 2015-08-19 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN105939712A (zh) 2013-12-03 2016-09-14 细胞内治疗公司 新方法
WO2015136090A1 (en) 2014-03-14 2015-09-17 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a cyclic radical
EP3116874B1 (en) 2014-03-14 2018-02-28 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a substituted alkyl radical
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
PT3407888T (pt) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
WO2017165843A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2017165755A1 (en) * 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US20210009592A1 (en) * 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
JP2022539821A (ja) 2019-07-07 2022-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4421070A1 (en) * 2021-10-18 2024-08-28 Sapiensbio Inc. Novel compound and pharmaceutical composition comprising same
KR102600176B1 (ko) * 2021-10-18 2023-11-10 주식회사 사피엔스바이오 신규한 화합물 및 이를 포함하는 약학적 조성물
KR102715926B1 (ko) * 2022-06-10 2024-10-15 주식회사 사피엔스바이오 신규한 화합물 및 이를 유효성분으로 포함하는 약학적 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714149A (en) 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
ATE117688T1 (de) 1989-06-09 1995-02-15 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
AU5704898A (en) * 1996-12-16 1998-07-15 Warner-Lambert Company Tricyclic quinoxaline derivatives as neuroprotective agents
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
AU2002227170A1 (en) * 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20080146583A1 (en) 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
PL1737850T3 (pl) 2004-04-19 2008-02-29 Symed Labs Ltd Nowy sposób wytwarzania linezolidu i związków pokrewnych
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
AU2007230997A1 (en) 2006-03-24 2007-10-04 Wyeth Treatment of pain
PE20080125A1 (es) 2006-03-24 2008-04-07 Wyeth Corp Metodo para modular la funcion de la vejiga
AR060087A1 (es) 2006-03-24 2008-05-21 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento de la depresion
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
MX2011011182A (es) * 2009-04-23 2012-02-21 Abbott Lab Moduladores de los receptores 5-ht y metodos de uso de los mismos.
US20140080813A1 (en) * 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives

Also Published As

Publication number Publication date
CA2884548A1 (en) 2014-03-20
KR20150056608A (ko) 2015-05-26
IL237726A0 (en) 2015-05-31
IN2015DN02070A (es) 2015-08-14
AU2013314279A1 (en) 2015-04-02
WO2014041131A1 (en) 2014-03-20
CR20150186A (es) 2015-08-28
AU2018200572A1 (en) 2018-02-15
AU2013314279B2 (en) 2017-11-02
US10118926B2 (en) 2018-11-06
TW201414735A (zh) 2014-04-16
JP6290217B2 (ja) 2018-03-07
CL2015000628A1 (es) 2015-10-30
AR092568A1 (es) 2015-04-22
PE20150777A1 (es) 2015-06-20
EP2895485A1 (en) 2015-07-22
BR112015005743A2 (pt) 2017-07-04
CN104995191A (zh) 2015-10-21
HK1212684A1 (zh) 2016-06-17
JP2015528478A (ja) 2015-09-28
US20200283439A1 (en) 2020-09-10
MX2015003364A (es) 2016-03-31
SG11201501894VA (en) 2015-04-29
UA116216C2 (uk) 2018-02-26
PH12015500551A1 (en) 2015-05-04
US20140080816A1 (en) 2014-03-20
US20190071443A1 (en) 2019-03-07
UY35029A (es) 2014-04-30
RU2015113558A (ru) 2016-11-10
ECSP15012766A (es) 2017-06-30
NZ631187A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
DOP2015000058A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2018000883A1 (es) Moduladores del receptor x farnesoide
CL2018001172A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
PE20151901A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2015002501A1 (es) Compuestos y usos de estos para la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
CL2015003271A1 (es) Derivados de ester de moduladores del receptor de andrógeno y métodos para su uso.
CO7111274A2 (es) Moduladores dll3 y métodos de empleo
UY34742A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2014001853A1 (es) Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario.
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
BR112018000468A2 (pt) 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.